Success Stories
Highlights of the PCI news focused on Penn commercialization accomplishments
FY22 President’s Innovation Prizes Awarded
Awarded annually, the President’s Innovation Prize empowers Penn students to design and undertake a post-graduation startup company that makes a positive, lasting difference in the world.
New ASSET Center
Penn Engineering’s newly formed ASSET (AI-enabled Systems: Safety, Explainablity and Trustworthiness) Center is part of Penn Engineering’s Innovation in Data Engineering & Science (IDEAS) Initiative.
Austin Alumni host SXSW Pitch Program
For the 5th year, PCI partnered with the Penn Wharton Austin Alumni group to host a startup pitch session in conjunction with SXSW Interactive.
Cleantech innovation for CO2 capture moves forward through Heirloom Carbon Technologies
PCI, along with Columbia University and the University of British Columbia, recently completed a license agreement with Heirloom Carbon Technologies.
IBA partners with Penn Medicine to develop flash therapy
IBA Worldwide, a technology company that develops particle accelerator technology, partnered with a team of faculty from Radiation Oncology at Penn Medicine led by Dr. James Metz.
Vivodyne named #1 “Small but Mighty” Company
Launched in 2021, Vivodyne’s platform allows fully automated, complex studies at a far larger scale and lower cost than would be possible with manual experimentation.
Wellcome Leap Funds Penn to develop “on-demand” manufacturing technology for RNA-based vaccines
Penn Engineering secured a multi-million-dollar contract with Wellcome Leap under the organization’s $60 million RNA Readiness + Response (R3) program.
Inspiring people, place, and purpose
Gutmann spearheaded the creation of an innovation ecosystem for Penn, Philadelphia, and beyond by transforming technology transfer at Penn to be both more faculty- and industry-friendly.
Decade-long remission after CAR T cell therapy
Two patients represent longest-known CAR T cell response to date, providing insight into treatment effect and outcomes.
Penn’s Gene Therapy Program signs manufacturing partnership with the Center for Breakthrough Medicines
The Center for Breakthrough Medicines and Penn’s Gene Therapy Program (GTP) entered into a multi-year collaboration focusing on the manufacturing and testing of modern gene therapy processes.